<DOC>
	<DOCNO>NCT00109200</DOCNO>
	<brief_summary>This continue access protocol provide subject complete Genentech , Inc. Study Q2143g , Q2195g , Q2461g Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 continue Xolair treatment . Subject eligibility base disease severity asthma deterioration upon withdrawal Xolair treatment . Subjects whose last Xolair dose &lt; 9 month prior screen visit continue Xolair dose regimen receive previous Genentech Novartis clinical study .</brief_summary>
	<brief_title>A Continued Access Protocol Provide Xolair Patients With Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Completion Genentech Study Q2143g , Q2195g , Q2461g Novartis Study CIGE025 0010E1 Signed inform consent document ( case minor , consent must give child 's parent legally authorize representative ) Females childbearing potential must , opinion investigator , use effective method contraception prevent pregnancy agree continue practice acceptable method contraception duration participation study . Severe asthma demonstrate least one following : *History prior intubation allergic asthma ; *History prior admission intensive care unit/pediatric ICU asthma ; *History one hospitalization , emergency room ( ER ) visit , unscheduled office visit asthma 12 month prior first Xolair treatment ; *More 20 day miss school/work allergic asthma 12 month prior initiation Xolair treatment Deterioration asthma upon withdrawal Xolair demonstrate meet least one following : *Worsening pulmonary function test ( FEV1 &lt; 80 % predict height , age , sex ) activity level Xolair treatment ; *Worsening asthma exacerbation define double inhaled steroid dose , increase dose oral steroid , initiation oral , intravenous , intramuscular , subcutaneous ( SC ) steroids Xolair treatment ; *Increased use rescue medication Xolair treatment ; *ER visit unscheduled office visit asthma may may result hospitalization Xolair treatment Pregnancy lactation Significant systemic disease ( e.g. , hematologic , renal , hepatic , coronary heart , endocrine , gastrointestinal disease , cardiovascular disease , infection ) within previous 3 month History neoplasia ( include basal cell carcinoma ) Any systemic condition require regular administration immunoglobulin Known hypersensitivity ingredient Xolair , include excipients ( sucrose , histidine , polysorbate 20 ) Current treatment warfarin ( Coumadin ( R ) ) , immunomodulatory therapy ( e.g. , methotrexate , gold , cyclosporine ) , antiplatelet therapy Current participation study use investigational new drug Xolair</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Allergic Asthma</keyword>
	<keyword>Severe Allergic Asthma</keyword>
</DOC>